Chất lượng cuộc sống của bệnh nhân lơ xê mi cấp dòng tuỷ cao tuổi điều trị bằng decitabine tại Viện Huyết học - Truyền máu Trung ương giai đoạn 2023-2024=Quality of life of elderly acute myeloid leukemia patients treated with decitabine at the National Institute of Hematology and Blood Transfusion in the period 2023-2024

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Quốc Khánh Bạch, Hà Thanhl Nguyễn, Quốc Nhật Nguyễn, Văn Nam Nguyễn

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.169-176

Bộ sưu tập: Metadata

ID: 478229

Thêm vào giỏ

Elderly patients who are ineligible for intensive chemotherapy are often treated with palliative regimens, supportive care, or enrolled in clinical trials for new drugs. The assessment of treatment outcomes in Acute Myeloid Leukemia (AML) should not only focus on survival rates but also include the patients' quality of life (QoL). Objective: To describe the quality of life of elderly AML patients treated with Decitabine at the National Institute of Hematology and Blood Transfusion during the period of 2023-2024. Subjects and Methods: A descriptive study was conducted on 70 elderly AML patients treated with the Decitabine regimen at the NIHBT from 2023 to 2024. Results and Conclusion: Patients’ quality of life was assessed before each treatment cycle using the EORTC QLQ-C30 questionnaire. Symptoms such as fatigue, loss of appetite, and financial difficulties significantly impacted patients' QoL. The QoL of elderly AML patients was found to be related to their pre-treatment performance status and their response to the Decitabine regimen. Decitabine not only provided hematological response but also improved the QoL in functional aspects and symptoms for elderly AML patients.Nhóm bệnh nhân cao tuổi, không đủ điều kiện hóa trị liệu tích cực thường được điều trị bằng các phác đồ giảm nhẹ, chăm sóc hỗ trợ hoặc tham gia thử nghiệm lâm sàng các thuốc mới. Đánh giá hiệu quả của điều trị Lơ xê mi cấp dòng tuỷ (AML) không chỉ dừng lại ở chỉ số sống sót mà còn bao gồm cả chất lượng cuộc sống (CLCS) của bệnh nhân. Mục tiêu: Khảo sát chất lượng cuộc sống của bệnh nhân AML cao tuổi điều trị bằng Decitabine tại Viện Huyết học – Truyền máu Trung ương giai đoạn 2023-2024. Đối tượng và phương pháp: Nghiên cứu mô tả trên 70 bệnh nhân AML cao tuổi được điều trị bằng phác đồ Decitabine tại Viện Huyết học – Truyền máu Trung Ương từ năm 2023- 2024. Kết quả và kết luận: Các bệnh nhân nghiên cứu được đánh giá chất lượng cuộc sống trước mỗi đợt điều trị bằng thang điểm EORTC QLQ-C30. Các triệu chứng mệt mỏi, chán ăn, khó khăn về tài chính ảnh hưởng nhiều đến CLCS của bệnh nhân. CLCS của bệnh nhân AML cao tuổi có mối liên quan với thể trạng của bệnh nhân trước điều trị và đáp ứng của bệnh nhân với phác đồ Decitabine. Decitabine không những mang lại đáp ứng về huyết học mà nó còn cải thiện CLCS trên các khía cạnh chức năng và triệu chứng của bệnh nhân AML cao tuổi.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR